Rafa Laboratories Ltd.


Rafa is a leading pharmaceutical company in Israel, founded in 1937, specializing in the manufacturing, marketing, and distribution of prescription and over-the-counter medicines. The company is committed to providing high therapeutic value products and has a strong focus on partnerships and innovation in the healthcare sector.

חברת התרופות רפא

Rafa Laboratories Ltd.

Shlomo Halevi 5, Jerusalem of Silver building, Har Hotzvim, P.O. 405, Jerusalem, 9777019


What We Do

Rafa offers a range of contract manufacturing services including bulk manufacturing, flexible batches, and primary and secondary packaging. The facility is designed for solid, semi-solid, sterile production, and liquids.

Rafa provides expertise in market access and pricing strategies to ensure successful product launches in the Israeli market.

The company specializes in sales and marketing strategies tailored to the lifecycle of products, ensuring maximum market penetration.

Rafa offers regulatory support including registration services and compliance expertise in Israeli, EMA, and FDA regulations.

The company provides pharmacovigilance services to monitor the safety of medicines post-marketing.

A life-saving product approved by the US-FDA for the treatment of status epilepticus in adults, developed in collaboration with the U.S. Department of Defense.



Key People

Plant Manager Director

VP of Business Development

VP, Commercial

VP, Regulatory Affairs, Pharmacovigilance, Medical Information


News & Updates

Rafa recently secured a 45 million $US deal with the US Department of Defense for its midazolam autoinjector which was approved by the US-FDA in 2022.

Rafa Laboratories LTD. is pleased to announce the U.S. Food and Drug Administration has approved its 'first in market' 10 mg midazolam autoinjector for the treatment of status epilepticus in adults.